Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.37 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891613 | 0.77 | CHRNB2 (0.37) | CHRNB2CHRNA4 | |
| SCHEMBL38660384 | 0.77 | CHRNB2 (0.37) | CHRNB2CHRNA4 | |
| SCHEMBL5512836 | 0.76 | KMT2A (0.37) | KMT2AMAPTHDAC1HDAC6CHRNB2 | |
| SCHEMBL31026422 | 0.76 | NNMT (0.44) | KMT2AMAPTCHRNB2CHRNA4MEN1 | |
| SCHEMBL2201487 | 0.76 | NNMT (0.44) | KMT2AMAPTCHRNB2CHRNA4MEN1 | |
| SCHEMBL30681884 | 0.76 | — | — | |
| SCHEMBL29241951 | 0.75 | MPO (0.43) | HDAC1HDAC6 | |
| SCHEMBL30726705 | 0.75 | MPO (0.43) | HDAC1HDAC6 | |
| SCHEMBL1890852 | 0.75 | CHRNB2 (0.38) | CHRNB2CHRNA4 | |
| SCHEMBL27657607 | 0.75 | CHRNA3 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119591600-A | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and use thereof | 上海瑛派药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119591599-A | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and use thereof | 上海瑛派药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119564686-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119523983-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119424429-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-114423756-B | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and use thereof | 上海瑛派药业有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-115003665-B | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118055924-A | Pyridyl-containing compounds | 正大天晴药业集团股份有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-116041399-A | Octahedral cage embedded with ether bond metal organic palladium, and preparation method and application thereof | 江苏科技大学 | 2023-05-02 | — | — | CN | disclosed |
| CN-109134492-B | Thienopyrimidone compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2021-08-13 | — | — | CN | disclosed |
| EP-3072893-B1 | KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF | BEIJING FORELANDPHARMA CO LTD (CN) | 2020-03-18 | — | — | EP | disclosed |
| US-20160304510-A1 | IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BEIJING FORELANDPHARMA CO. LTD. (CN) | 2016-10-20 | — | — | US | disclosed |
| EP-3072893-A1 | KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF | Beijing Forelandpharma Co. Ltd. (CN) | 2016-09-28 | — | — | EP | disclosed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1736472-A1 | 2-AMINOPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304510-A1 | IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DMPK, MAP3K15, MAP4K2 | KMT2A 3498/4885MAPT 2230/4885HDAC1 907/4885 |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | NFKBIA, IKBKG, NFKB2 | KMT2A 469/4885MAPT 3882/4885HDAC1 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.